Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis

Authors:

Abstract
No abstract available
Funding Information
  • Winship Cancer Institute

This publication has 28 references indexed in Scilit: